Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study
Diego Kauffmann‐Guerrero, Kathrin Kahnert, Rosemarie Kiefl, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 58

Showing 1-25 of 58 citing articles:

Predictive value of serum cytokines in patients with non-small-cell lung cancer receiving anti-PD-1 blockade therapy: a meta-analysis
Qian Liu, Zakari Shaibu, Aiguo Xu, et al.
Clinical and Experimental Medicine (2025) Vol. 25, Iss. 1
Open Access | Times Cited: 2
Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives
Ying Yang, Hongyang Liu, Youming Chen, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 3
Open Access | Times Cited: 36
Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies
Suna Zhou, Haihua Yang
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 30
Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures
Feifei Wei, Koichi Azuma, Yoshiro Nakahara, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 7, pp. e006788-e006788
Open Access | Times Cited: 25
Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade
Yo-Ting Tsai, Jeffrey Schlom, Renee N. Donahue
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 13
Immune checkpoint inhibitors in colorectal cancer: limitation and challenges
Suying Yan, Wanting Wang, Zhiqiang Feng, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 10
Circulating biomarkers as predictors of response to immune checkpoint inhibitors in NSCLC: Are we on the right path?
Calogera Claudia Spagnolo, Francesco Pepe, Giuliana Ciappina, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 197, pp. 104332-104332
Open Access | Times Cited: 7
Prognostic Effect of the Controlling Nutritional Status Score in Patients With Esophageal Cancer Treated With Immune Checkpoint Inhibitor
Lele Chang, Qian Cheng, Yue Ma, et al.
Journal of Immunotherapy (2022) Vol. 45, Iss. 9, pp. 415-422
Open Access | Times Cited: 24
Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC
Kah Yee Goh, Terence You De Cheng, Su Chin Tham, et al.
Biomedicines (2023) Vol. 11, Iss. 2, pp. 508-508
Open Access | Times Cited: 14
Prognostic and clinicopathological significance of Systemic Immune-Inflammation Index in cancer patients receiving immune checkpoint inhibitors: a meta-analysis
Yan Wang, Qunqin Ni
Annals of Medicine (2023) Vol. 55, Iss. 1, pp. 808-819
Open Access | Times Cited: 14
Mechanisms and Strategies of Immunosenescence Effects on Non-Small Cell Lung Cancer (NSCLC) Treatment: A Comprehensive Analysis and Future Directions
Huatao Zhou, Zilong Zheng, Chengming Fan, et al.
Seminars in Cancer Biology (2025) Vol. 109, pp. 44-66
Closed Access
IL-17 triggers PD-L1 gene transcription in NSCLC cells via TRIM31-dependent MEF2C K63-linked polyubiquitination
Shuai Ying, Ningxia Wu, Yuting Ruan, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer
Yurong Peng, Zhuo Li, Yucheng Fu, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 12
The Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions
Angela Rina, Debora Maffeo, Francesca Minnai, et al.
Cancers (2024) Vol. 16, Iss. 16, pp. 2882-2882
Open Access | Times Cited: 4
Predictive biomarkers for immune checkpoint inhibitors therapy in lung cancer
Jie Yao, Xuwen Lin, Xin Zhang, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 4
Systemic Immune-Inflammation Index as a Predictor of Survival in Non-Small Cell Lung Cancer Patients Undergoing Immune Checkpoint Inhibition: A Systematic Review and Meta-Analysis
Ye Zhang, Yeye Chen, Chao Guo, et al.
Critical Reviews in Oncology/Hematology (2025), pp. 104669-104669
Closed Access
Prediction, prevention, and precision treatment of immune checkpoint inhibitor neurological toxicity using autoantibodies, cytokines, and microbiota
Alberto Vogrig, Marta Dentoni, Irene Florean, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
M1 Macrophages Induce Protumor Inflammation in Melanoma Cells through TNFR–NF-κB Signaling
Kirsi Kainulainen, Piia Takabe, Sami Heikkinen, et al.
Journal of Investigative Dermatology (2022) Vol. 142, Iss. 11, pp. 3041-3051.e10
Open Access | Times Cited: 17
A Wnt-induced lncRNA-DGCR5 splicing switch drives tumor-promoting inflammation in esophageal squamous cell carcinoma
Yue Li, Boyu Chen, Xingyu Jiang, et al.
Cell Reports (2023) Vol. 42, Iss. 6, pp. 112542-112542
Open Access | Times Cited: 10
Circulating IL-6 is associated with disease progression in BRAFwt metastatic melanoma patients receiving anti-PD-1 therapy
Katarina Mirjačić Martinović, Ana Vuletić, Nevena Tišma Miletić, et al.
Journal of Clinical Pathology (2023) Vol. 77, Iss. 5, pp. 343-351
Closed Access | Times Cited: 9
Cytokine profiling identifies circulating IL-6 and IL-15 as prognostic stratifiers in patients with non-small cell lung cancer receiving anti-PD-1/PD-L1 blockade therapy
Yusuke Inoue, Naoki Inui, Masato Karayama, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 8, pp. 2717-2728
Closed Access | Times Cited: 9
Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort study
Dominik A. Barth, Florian Moik, Sarah Steinlechner, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 12, pp. e007765-e007765
Open Access | Times Cited: 9
CD34+DNAM-1brightCXCR4+ haemopoietic precursors circulate after chemotherapy, seed lung tissue and generate functional innate-like T cells and NK cells
Carola Perrone, Federica Bozzano, Maria Giovanna Dal Bello, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Emerging Blood-Based Biomarkers for Predicting Immunotherapy Response in NSCLC
Ana Oitabén, Pablo Fonseca, María José Villanueva, et al.
Cancers (2022) Vol. 14, Iss. 11, pp. 2626-2626
Open Access | Times Cited: 15
Advancing cancer immunotherapy: from innovative preclinical models to clinical insights
Andrew W.B. Craig, Hermann B. Frieboes, Paula A. Videira
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top